Clinical Pharmacokinetics

, Volume 32, Issue 5, pp 345–356 | Cite as

The Electronic Medication Event Monitor

Lessons for Pharmacotherapy
Current Opinion


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kass MA, Zimmerman T, Yablonski M, et al. Compliance to pilocarpine therapy [abstract no.2]. Invest Ophthalmol 1977; 108:2Google Scholar
  2. 2.
    Kass MA, Meltzer D, Gordon M. A miniature compliance monitor for ophthalmology. Arch Ophthalmol 1984; 102: 1550PubMedCrossRefGoogle Scholar
  3. 3.
    Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–7PubMedCrossRefGoogle Scholar
  4. 4.
    Averbuch M, Weintraub M, Pollack DJ. Compliance assessment in clinical trials: the MEMS device. J Clin Res Pharmacoepidemiol 1990; 4: 199–204Google Scholar
  5. 5.
    Kruse W, Weber E. Dynamics of drug regimen compliance: its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990; 38: 561–5PubMedCrossRefGoogle Scholar
  6. 6.
    Tashkin DP, Rand C, Nides M, et al. A nebulizer chronolog to monitor compliance with inhaler use. Am J Med 1991; 91 Suppl. 4A: 33S–6SPubMedCrossRefGoogle Scholar
  7. 7.
    Mawhinney H, Spector SL, Kinsman RA, et al. Compliance in clinical trials of two nonbronchodilator, antiasthma medications. Ann Allergy 1991; 66: 294–9PubMedGoogle Scholar
  8. 8.
    Eisen SA, Woodward RS, Miller D, et al. The effect of medication compliance on the control of hypertension. J Gen Intern Med 1987; 2: 298–305PubMedCrossRefGoogle Scholar
  9. 9.
    Cheung R, Dickins J, Nicholson PW, et al. Compliance with anti-tuberculous therapy: a field trial of a pill-box with a concealed recording device. Eur J Clin Pharmacol 1988; 35:401–7PubMedCrossRefGoogle Scholar
  10. 10.
    Potter LS. Oral contraceptive compliance and its role in the effectiveness of the method. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991: 195–207Google Scholar
  11. 11.
    Urquhart J. Role of patient compliance in clinical pharmacokinetics: review of recent research. Clin Pharmacokinet 1994; 27:202–15PubMedCrossRefGoogle Scholar
  12. 12.
    Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Inf J 1988; 22: 363–78Google Scholar
  13. 13.
    Tritsmans L, Clincke G, Peelmans B. Does AAMI constitute a real disease entity? A placebo-controlled double-blind study with sabeluzole (R 58 735) in a patient population with real memory problems. Drug Dev Res 1990; 20: 473–82CrossRefGoogle Scholar
  14. 14.
    Matsui D, Hermann C, Braudo M, et al. Clinical use of the Medication Event Monitoring System: a new window into pediatric compliance. Clin Pharmacol Ther 1992; 52: 102–3PubMedCrossRefGoogle Scholar
  15. 15.
    Matsuyama JR, Mason BJ, Jue SG. Pharmacists’ interventions using an electronic medication-event monitoring device’s adherence data versus pill counts. Ann Pharmacother 1993; 27: 851–5PubMedGoogle Scholar
  16. 16.
    Steiner TJ, Catarci T, Hering R, et al. If migraine prophylaxis does not work, think about compliance. Cephalalgia 1994; 14: 463–4PubMedCrossRefGoogle Scholar
  17. 17.
    Mason BJ, Matsuyama JR, Jue SG. Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ 1995; 21: 52–7PubMedCrossRefGoogle Scholar
  18. 18.
    Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res 1994; 22: 266–72PubMedGoogle Scholar
  19. 19.
    Rudd P, Ahmed S, Zachary V, et al. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990; 48: 676–85PubMedCrossRefGoogle Scholar
  20. 20.
    Kruse W, Eggert-Kruse W, Rampmaier J, et al. Compliance and adverse drug reactions: a prospective study with ethinylestradiol using continuous compliance monitoring. Clin Investig 1993; 71: 483–7PubMedCrossRefGoogle Scholar
  21. 21.
    Mengden T, Binswanger B, Spühler T, et al. The use of selfmeasured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens 1993; 11: 1403–11PubMedCrossRefGoogle Scholar
  22. 22.
    Kruse W, Rampmaier J, Ullrich G, et al. Patterns of drug compliance with medication to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 1994; 32: 453–7Google Scholar
  23. 23.
    Cramer J, Vachon L, Desforges C, et al. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995; 36: 1111–7PubMedCrossRefGoogle Scholar
  24. 24.
    de Klerk E, van der Linden SJ. Compliance monitoring of NSAID drug-therapy in ankylosing spondylitis, experiences with an electronic monitoring device. Br J Rheumatol 1996; 35: 60–5PubMedCrossRefGoogle Scholar
  25. 25.
    Mallion JM, Dutrey-Dupagne C, Vaur L, et al. Comportement des patients ayant une hypertension arterielle legère a modrée vis-à-vis de leur traitement: apport du pilulier électronique. Ann Cardiol Angeiol 1995; 44: 597–605Google Scholar
  26. 26.
    Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995; 49: 321–7PubMedCrossRefGoogle Scholar
  27. 27.
    Girard P, Sheiner LB, Kastrissios H, Blaschke TF. A markov model for drug compliance, with application to HI V+ patients [abstract]. Clin Pharmacol Ther 1996; 59: 157CrossRefGoogle Scholar
  28. 28.
    de Klerk E, van der Linden SJ, van der Heijden D, et al. Facilitated analysis of data on drug regimen compliance. Stat Med. In pressGoogle Scholar
  29. 29.
    Rubin D. Comment: dose-response estimands. J Am Stat Assoc 1991; 86(413): 22–4Google Scholar
  30. 30.
    Urquhart J. Patient compliance as an explanatory variable in four selected cardiovascular studies. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991: 301–22Google Scholar
  31. 31.
    Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. J Am Stat Assoc 1991; 86(413): 9–17CrossRefGoogle Scholar
  32. 32.
    Hasford J. Biometric issues in measuring and analyzing partial compliance in clinical trials. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991: 265–81Google Scholar
  33. 33.
    Sheiner LB, Rubin DB. Intention to treat analysis and the goals of clinical trials. Clin Pharmacol Ther 1995; 57: 6–15PubMedCrossRefGoogle Scholar
  34. 34.
    Goetghebeur EJT, Pocock SJ. Statistical issues in allowing for noncompliance and withdrawal. Drug Inf J 1993; 27: 837–45CrossRefGoogle Scholar
  35. 35.
    Mäenpää H, Manninen V, Heinonen OP. Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J 1987; 8 Suppl. I: 39–43PubMedGoogle Scholar
  36. 36.
    Pullar T, Kumar S, Tindall H, et al. Time to stop counting the tablets? Clin Pharmacol Ther 1989; 46: 163–8PubMedCrossRefGoogle Scholar
  37. 37.
    Pullar T, Feely M. Problems of compliance with drug treatment: new solutions? Pharm J 1990; 245: 213–5Google Scholar
  38. 38.
    Temple R. Dose-response and registration of new drugs. In: Lasagna L, Erill S, Naranjo CA, editors. Dose-response relationships in clinical pharmacology. Amsterdam: Elsevier, 1989: 145–67Google Scholar
  39. 39.
    Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993; 11: 1189–97PubMedGoogle Scholar
  40. 40.
    Guerrero D, Rudd P, Bryant-Kosling C, et al. Antihypertensive medication-taking: investigation of a simple regimen. Am J Hypertens 1993; 6: 586–92PubMedGoogle Scholar
  41. 41.
    Kruse W, Nikolaus T, Rampmaier J, et al. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharmacol 1993; 44: 211–5CrossRefGoogle Scholar
  42. 42.
    Benet LZ, Øie S, Schwartz J. Design and optimization of dosage regimens: pharmacokinetic data. Appendix II. In: Hardman JG, Limbird LE, Molinoff PB, et al. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1707–92Google Scholar
  43. 43.
    Benet LZ, Kroetz DL, Sheiner LB. Therapeutic drug monitoring. In Hardman JG, Limbird LE, Molinoff PB, et al. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:26Google Scholar
  44. 44.
    Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150: 1377–8PubMedCrossRefGoogle Scholar
  45. 45.
    Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet 1992; 22: 238–46PubMedCrossRefGoogle Scholar
  46. 46.
    Urquhart J. Correlates of variable patient compliance in drug trials: relevance in the new health care environment. In: Testa B, Meyer UA. Advances in drug research. London: Academic Press, 1995: 238–57Google Scholar
  47. 47.
    McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994; 50 Suppl. 1: S9–S195CrossRefGoogle Scholar
  48. 48.
    NORPLANT System. Physicians’ Desk Reference. 50th ed. Oradell (NJ): Medical Economics, 1996: 2759–64Google Scholar
  49. 49.
    Grimes DA. Clinical crossroads: a 17-year old mother seeking contraception. JAMA 1996; 276: 1163–70PubMedCrossRefGoogle Scholar
  50. 50.
    British National Formulary, no. 32. Sep 1996: 338Google Scholar
  51. 51.
    ORTHO-NOVUM Tablets. Physicians’ Desk Reference. 50th ed. Oradell (NJ): Medical Economics, 1996: 1872–80Google Scholar
  52. 52.
    Johnson BF, Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am J Ther 1994; 1:260–7PubMedCrossRefGoogle Scholar
  53. 53.
    Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol, andpindolol. Am Heart J 1982; 104:473–8PubMedCrossRefGoogle Scholar
  54. 54.
    Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988; 116:515–23PubMedCrossRefGoogle Scholar
  55. 55.
    Gilligan DM, Chan WL, Stewart R, et al. Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol 1991; 68: 766–72PubMedCrossRefGoogle Scholar
  56. 56.
    Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers. JAMA 1990; 263: 1653–7PubMedCrossRefGoogle Scholar
  57. 57.
    Feinstein AR, Spagnuolo M. Experimental reactivation of subsiding rheumatic fever. J Clin Invest 1961; 40: 1891–9PubMedCrossRefGoogle Scholar
  58. 58.
    Didlake RH, Dreyfus K, Kerman RH, et al. Patient noncompliance: a major cause of late graft failure in cyclosporinetreated renal transplants. Transplant Proc 1988; 20 Suppl. 3: 63–9PubMedGoogle Scholar
  59. 59.
    Rovelli M, Palmeri D, Vossler E, et al. Noncompliance in organ transplant recipients. Transplant Proc 1989; 21(1): 833–4PubMedGoogle Scholar
  60. 60.
    De Geest S. Subclinical noncompliance with immunosuppressive therapy in heart transplant patients: a cluster analytic study [dissertation]. Leuven: Catholic University Leuven, 1995Google Scholar
  61. 61.
    Cramer JA. Compliance with contraceptives and other treatments. Obstet Gynecol 1996; 88 Suppl.: 4S–12SPubMedCrossRefGoogle Scholar
  62. 62.
    Petri H, Urquhart J. Patient compliance with beta-blocker medication in general practice. Pharmacoepidemiol Drug Saf 1994; 3: 251–6CrossRefGoogle Scholar
  63. 63.
    Guillebaud J. Any questions. BMJ 1993; 307: 617Google Scholar
  64. 64.
    QUESTRAN (cholestyramine). Physicians’ desk reference. 50th ed. Oradell (NJ): Medical Economics, 1995: 770–1Google Scholar
  65. 65.
    The Lipid Research Clinic. The Lipid Research Clinic’s coronary primary prevention trial results: (I) reduction in incidence of coronary heart disease; (II) the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 351–74CrossRefGoogle Scholar
  66. 66.
    Lasagna L, Hutt PB. Health care, research, and regulatory impact of noncompliance. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991:393–403Google Scholar
  67. 67.
    Vander Stichele RH, Thomson M, Verkoelen K, et al. Measuring patient compliance with electronic monitoring: lisinopril versus atenolol in essential hypertension. Post-marketing Surveillance 1992; 6: 77–90Google Scholar
  68. 68.
    Petzinna D. Electronic compliance measurement and fraud. A A Drug Information Association Workshop on Drug Compliance Issues in Clinical Trials & Patient Care. 1996 Sept 30-Oct 1; Paris, 12Google Scholar
  69. 69.
    Kass MA, Meltzer D, Gordon M, et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986; 101: 515–23PubMedGoogle Scholar
  70. 70.
    Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol 1986; 101:524–30PubMedGoogle Scholar
  71. 71.
    Kass MA, Gordon M, Morley RE, et al. Compliance with topical timolol treatment. Am J Ophthalmol 1987; 103: 188–93PubMedGoogle Scholar
  72. 72.
    Geletko, SM, Segarra M, Mayer KH, et al. Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women. Antimicrob Agents Chemother 1996; 40: 1338–41PubMedGoogle Scholar
  73. 73.
    Bakker A, Paes AHP, Soe-Agnie C. Improving compliance of oral antidiabetics through pharmacist’s intervention [abstract]: proceedings of the 23rd European symposium on clinical trials and pharmacoharmaco-epidemiology. Pharm World Sci 1994; Suppl. 6: G28Google Scholar
  74. 74.
    Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348: 383–6PubMedCrossRefGoogle Scholar
  75. 75.
    Norell SE. Methods in assessing drug compliance. Acta Med Scand Suppl 1984; 683: 35–40PubMedGoogle Scholar
  76. 76.
    Weis SE, Slocum PC, Biais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179–84PubMedCrossRefGoogle Scholar
  77. 77.
    Wasson J, Gaudette C, Whaley F, et al. Telephone care as a substitute for routine clinical follow-up. JAMA 1992; 267: 1788–93PubMedCrossRefGoogle Scholar
  78. 78.
    Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190–5PubMedCrossRefGoogle Scholar
  79. 79.
    Stanford ’Multifit’ CHF disease management program reduces ER visits by 52% in trial at Kaiser: medication compliance infrastructure is key, Stanford feels. Washington, DC, F-D-C Reports, 1 July 1996: 13-4Google Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.Department of EpidemiologyMaastricht UniversityMaastrichtThe Netherlands

Personalised recommendations